WASHINGTON, D.C. 20549

                                   FORM 12B-25
                           SEC FILE NUMBER: 002-90539
                           CUSIP NUMBER: 03815U 10 2.

                           NOTIFICATION OF LATE FILING

(Check One): [ ]Form 10-K    [ ]Form 20-F    [ ]Form 11-K    [x]Form 10-QSB
             [ ]Form NSAR

                        For Period Ended: March 31, 2004

                  [ ] Transition Report on Form 10-K
                  [ ] Transition Report on Form 20-F
                  [ ] Transition Report on Form 11-K
                  [ ] Transition Report on Form 10-Q
                  [ ] Transition Report on Form N-SAR

For the Transition Period Ended:

If the notification relates to a portion of the filing checked above, identify
the Item(s) to which the notification relates:

Full Name of Registrant: Applied DNA Sciences, Inc.
Address of Principal Executive Office:  9229 Sunset Boulevard, Suite 830,
                                        Los Angeles, CA 90069

PART II -- RULES 12B-25(B) AND (C)

If the subject report could not be filed without unreasonable effort or expense
and the registrant seeks relief pursuant to Rule 12b-25(b), the following should
be completed. (Check box if appropriate)[x]

(a) The reasons described in reasonable detail in Part III of this form could
not be eliminated without unreasonable effort or expense;

(b) The subject annual report, semi-annual report, transition report on Form
10-K, Form 20-F,11-K or Form N-SAR, or portion thereof, will be filed on or
before the fifteenth calendar day following the prescribed due date; or the
subject quarterly report of transition report on Form 10-QSB, or portion thereof
will be filed on or before the fifth day of the due date. [X]

(c) The accountant's statement or other exhibit required by Rule 12b-25(c) has
been attached if applicable.


State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q,
N-SAR, or the transition report portion thereof, could not be filed within the
prescribed time period.

The Issuer lacked certain financial data and other information required to
complete the filing, and such data and information could not have been made
available without unreasonable effort and expense.


(1) Name and telephone number of person to contact in regard to this


Andrea Cataneo, Esq. (973) 442-9944
-------------------- ---------------
(Name)               (Phone number)

(2) Have all other periodic reports required under Section 13 or 15(d) of the
Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of
1940 during the preceding 12 months or for such shorter period that the
registrant was required to file such report(s) been filed? If answer is no,
identify report(s). Yes

(3) Is it anticipated that any significant change in results of operations from
the corresponding period for the last fiscal year will be reflected by the
earnings statements to be included in the subject report or portion thereof? No
If so, attach an explanation of the anticipated change, both narratively and
quantitatively, and, if appropriate, state the reasons why a reasonable estimate
of the results cannot be made.

Applied DNA Sciences, Inc.
(Name of Registrant as Specified in Charter)
has caused this notification to be signed on its behalf by the undersigned
hereunto duly authorized.

Date:  May 16, 2004

By: /s/ Gerhard Wehr
Gerhard Wehr, Chief Financial Officer and Director